Roche says comparison study for its Gazyva/ Gazyvaro showed superior progression-free survival in follicular lymphoma

pharmafile | May 27, 2016 | News story | Medical Communications, Research and Development Comparison Study, Roche, drug trial, follicular lymphoma 

Roche (SIX: ROG) on Friday said late-stage comparison trials for its drug to treat a slower form of non-Hodgkin lymphoma showed significant progression-free survival over the other treatment.

The results showed that Gazyva/ Gazyvaro-based treatment significantly reduced the risk of disease worsening or death compared to MabThera/ Rituxan-based treatment.

The comparison study tested the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy followed by Gazyva/Gazyvaro alone, head-to-head with MabThera/Rituxan (rituximab) plus chemotherapy followed by MabThera/Rituxan alone.

Sandra Horning, chief medical officer said: “People with follicular lymphoma continue to need better initial treatment options because their disease is incurable and becomes more difficult to treat with each relapse. Gallium is the second study in which Gazyva/Gazyvaro showed superior progression-free survival compared to MabThera/Rituxan, when each was combined with chemotherapy.”

Follicular lymphoma is the most common indolent (slow-growing) form of non-Hodgkin lymphoma (NHL), accounting for about one in five cases of NHL. It is considered incurable and relapse is common. It is estimated that more than 75,000 people are diagnosed with follicular lymphoma each year worldwide.

Anjali Shukla

Related Content

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) …

Roche announces acquisition of Telavant

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, …

EC approves Roche’s Evrysdi for babies under two months with SMA

Roche has announced that the European Commission (EC) has approved the extension of Evrysdi’s marketing …

Latest content